Comparison of a new ELISA-based with the flow cytometric assay for vasodilator-associated stimulated phosphoprotein phosphorylation to assess P2Y12-inhibition after ticagrelor intake

Cytometry Part B - Clinical Cytometry

Volumn 88, Issue 6, 2015, Pages 385-388

  Hobl, Eva Luise ^a   Jilma, Bernd ^a   Derhaschnig, Ulla ^a   Schoergenhofer, Christian ^a   Schwameis, Michael ^a   Jilma Stohlawetz, Petra ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

ELISA; flow cytometry; P2Y12 inhibition; ticagrelor; VASP

Indexed keywords

PURINERGIC P2Y12 RECEPTOR; TICAGRELOR; VASODILATOR AGENT; ACTIN BINDING PROTEIN; ADENOSINE; ANTITHROMBOCYTIC AGENT; CELL ADHESION MOLECULE; CLOPIDOGREL; P2RY12 PROTEIN, HUMAN; PHOSPHOPROTEIN; TICLOPIDINE; VASODILATOR-STIMULATED PHOSPHOPROTEIN;

ADULT; ARTICLE; ASSAY; CONTROLLED STUDY; DILUTION; DRUG BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN EXPERIMENT; INTERMETHOD COMPARISON; LOADING DRUG DOSE; MALE; NORMAL HUMAN; PLATELET REACTIVITY; PRIORITY JOURNAL; RECEPTOR BLOCKING; THROMBOCYTE ACTIVATION; VASODILATOR ASSOCIATED STIMULATED PHOSPHOPROTEIN VASODILATOR ASSOCIATED STIMULATED PHOSPHOPROTEIN; ADOLESCENT; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; DRUG EFFECTS; IMMUNOLOGY; PHOSPHORYLATION; PROCEDURES; PROSPECTIVE STUDY; THROMBOCYTE AGGREGATION; YOUNG ADULT;

ADENOSINE; ADOLESCENT; ADULT; CELL ADHESION MOLECULES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MICROFILAMENT PROTEINS; PHOSPHOPROTEINS; PHOSPHORYLATION; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; RECEPTORS, PURINERGIC P2Y12; TICLOPIDINE; YOUNG ADULT;

EID: 84945464898     PISSN: 15524949     EISSN: 15524957     Source Type: Journal    
DOI: 10.1002/cyto.b.21119     Document Type: Article

References (15)

1. Kohli P, Wallentin L, Reyes E, Horrow J, Husted S, Angiolillo DJ, Ardissino D, Maurer G, Morais J, Nicolau JC, et al., Reduction in first and recurrent cardiovascular events with ticagrelor compared with Clopidogrel in the PLATO study. Circulation 2013; 127: 673-680.
2. Bliden KP, Tantry US, Storey RF, Jeong YH, Gesheff M, Wei C, Gurbel PA,. The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: Combined analysis of the ONSET/OFFSET and RESPOND studies. Am Heart J 2011; 162: 160-165.
3. Bonello L, Mancini J, Pansieri M, Maillard L, Rossi P, Collet F, Jouve B, Wittenberg O, Laine M, Michelet P, et al., Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel. J Thromb Haemost 2012; 10: 1999-2005.
4. Harrison P,. Advances in the monitoring of anti-P2Y(12) therapy. Platelets 2012; 23: 510-525.
5. Barragan P, Bouvier JL, Roquebert PO, Macaluso G, Commeau P, Comet B, Lafont A, Camoin L, Walter U, Eigenthaler M,. Resistance to thienopyridines: Clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 2003; 59: 295-302.
6. Blindt R, Stellbrink K, de Taeye A, Muller R, Kiefer P, Yagmur E, Weber C, Kelm M, Hoffmann R,. The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis. Thromb Haemost 2007; 98: 1329-1334.
7. Frere C, Cuisset T, Quilici J, Camoin L, Carvajal J, Morange PE, Lambert M, Juhan-Vague I, Bonnet JL, Alessi MC,. ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thromb Haemost 2007; 98: 838-843.
8. Schwarz UR, Geiger J, Walter U, Eigenthaler M,. Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets-Definition and detection of ticlopidine/clopidogrel effects. Thromb Haemost 1999; 82: 1145-1152.
9. Siller-Matula JM, Christ G, Lang IM, Delle-Karth G, Huber K, Jilma B,. Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay. J Thromb Haemost 2010; 8: 351-359.
10. Bland JM, Altman DG,. Comparing methods of measurement: Why plotting difference against standard method is misleading. Lancet 1995; 346: 1085-1087.
11. Cannon CP,. Clopidogrel: To test or not to test? That is the question-Still. Clin Chem 2011; 57: 659-661.
12. Becker RC, Bassand JP, Budaj A, Wojdyla DM, James SK, Cornel JH, French J, Held C, Horrow J, Husted S, et al., Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J 2011; 32: 2933-2944.
13. Storey RF, Bliden KP, Ecob R, Karunakaran A, Butler K, Wei C, Tantry U, Gurbel PA,. Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared with clopidogrel in patients with high antiplatelet responses. J Thromb Haemost 2011; 9: 1730-1737.
14. Storey RF, Angiolillo DJ, Patil SB, Desai B, Ecob R, Husted S, Emanuelsson H, Cannon CP, Becker RC, Wallentin L,. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: The PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. J Am Coll Cardiol 2010; 56: 1456-1462.
15. Jakubowski JA, Bourguet N, Boulay-Moine D, Sugidachi A, Yamaguchi S, Barragan P, Zhou C, Moulard M,. Comparison of a new ELISA assay with the flow cytometric assay for platelet vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation in whole blood to assess P2Y(12) inhibition. Thromb Haemost 2012; 107: 388-395.